-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
April 2018
-
PD-L1 IHC Blueprint Project: Ongoing Progress Toward Consistency Among Assays
By Fred R. Hirsch, MD, PhD Posted: April 2018 Immunotherapy is a very encouraging development in the treatment of patients with lung cancer. At this phase of its refinement, we struggle with the challenge of how to select the right patients for the right treatment. Patient selection is paramount because only 20% to 30% of patients…
-
2017 Lung Cancer SPORE Workshop
By Roy S. Herbst, MD, PhD The National Cancer Institute’s (NCI’s) Lung Cancer Specialized Programs of Research Excellence (SPORE) and their affiliates met June 21-22, 2017, to discuss current trends in translational lung cancer research, plan collaborations, and design new projects. The event was hosted by Yale Cancer Center, the Yale SPORE in Lung Cancer…
-
FDA’s New Nicotine-Focused Regulatory Framework Supported by Evidence Reviews on Electronic Cigarettes
By K. Michael Cummings, PhD, MPH, andGraham Warren, MD, PhD Posted: April 2018 On July 28, 2017, the U.S. Food and Drug Administration (FDA) announced a new emphasis in the federal government’s regulatory framework toward tobacco product regulation. This new emphasis would focus on nicotine and would support innovations to promote tobacco harm reduction based…
-
Q&A with Dr. D. Ross Camidge
Posted: April 2018 In January 2018, the response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) working group—an international collaboration of cancer treatment, scientific, and imaging experts— published a new guideline on addressing central nervous system (CNS) metastases in clinical trial designs for systemic agents.1 IASLC Lung Cancer News caught up with the guidelines’ lead author D.…
-
Keeping It Personal: CMS-Proposed Coverage Restrictions for NGS Challenge Innovation in Personalized Care
By Jason N. Rosenbaum, MD, andDara L. Aisner, MD, PhD Posted: April 2018 Within the span of a few weeks, the U.S. Food and Drug Administration (FDA), the Center for Medicare and Medicaid Services (CMS), and the IASLC all issued guidelines, recommendations, or regulatory policy statements aimed at optimizing molecular testing for cancer.1-3 All three…
-
Breaking News Briefs
Tumors with high TMB responded well to combination in large patient population. By now the results of the phase III CheckMate-227 study are known by most. The primary endpoint of progression-free survival was met, and the immunotherapy (IO) combination of nivolumab and ipilimumab was proven superior to chemotherapy in the first line for patients with…
-
ESMO-IASLC European Lung Cancer Congress
The Heine Hansen Award recipient is IASLC Lung Cancer News Associate Editor Fabrice Barlesi, MD. His lecture will be “The Power of Multiple H.” “I’m unbelievably grateful to the ESMO and to the IASLC for this prestigious award, which honors not only me but all of the French teams that are diligently working in the…
-
European Perspective on ALCHEMIST
By Tiziana Vavalà, MD, andSilvia Novello, MD, PhD Posted: April 2018 Approximately 1.8 million new lung cancer cases worldwide are diagnosed annually, and 85% of these cases are NSCLC. Only 25% to 30% of patients with NSCLC are suitable for potentially curative resection. Despite optimal surgical management and postoperative treatments, nearly one-third of patients with…
-
Lung Cancer 360 Forum Overview: C.A.I.R.O Journal Club’s Fourth Anniversary
By C.A.I.R.O Journal Club Executive Board Posted: April 2018 In early February, the Critical Appraisal Initiative for Research in Oncology (C.A.I.R.O) Journal Club celebrated its fourth anniversary by hosting a Lung Cancer 360 Forum in the Bibliotheca Alexandrina. The Forum was a 2-day interactive educational event that gathered 205 senior and early-career oncology physicians and…
-
Q&A with TMB Expert Dr. Solange Peters
Posted: April 2018 Solange Peters, MD-PhD, PD-MER, runs the Thoracic Malignancies Program in the Department of Oncology at the University of Lausanne, Switzerland. Her main field of interest is new biomarker discovery and validation in preclinical/clinical settings, and she is also involved in developing multimodality trials for locally advanced NSCLC. She has been elected President…